Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Rallybio Looks To Deals To Grow ‘Transformative’ Rare Disease Pipeline

02 Mar 2022

• By Ayisha Sharma

• Source: Alamy

Related Content

Rallybio Leverages Founders’ Experience, $145m In New Cash For Rare Diseases

20 May 2020

Finance Watch: Ten IPOs In One Week Bring 2021 Total To 80

02 Aug 2021

Argenx Takes Slow But Steady Approach To Vyvgart Sales

29 Dec 2021

Related Companies

Rallybio Corp.

Alexion Pharmaceuticals Inc.

Swedish Orphan Biovitrum AB

AstraZeneca PLC

argenx N.V.

Exscientia plc

Additional Topics

Rare Diseases StartUps and SMEs Commercial Companies Emerging Company Profile Blood & Coagulation Disorders BioPharmaceutical

More from Emerging Company Profiles

More from Start-Ups & SMEs

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.